Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies.
about
Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System InfectionsReview of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaPrecision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive AstrocytesGlycoengineering of interferon-β 1a improves its biophysical and pharmacokinetic propertiesExploring Concordance of Patient-Reported Information on PatientsLikeMe and Medical Claims Data at the Patient LevelThe Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple SclerosisEarly treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE.Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.The meninges: new therapeutic targets for multiple sclerosis.Relationship between the Increased Haemostatic Properties of Blood Platelets and Oxidative Stress Level in Multiple Sclerosis Patients with the Secondary Progressive StageProteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis.Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyThe increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients.Creatine Enhances Mitochondrial-Mediated Oligodendrocyte Survival After Demyelinating InjuryIL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation.mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis.A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.Role of astrocytes in major neurological disorders: the evidence and implications.Multiple sclerosis and Parkinson's disease: the two faces of neurodegeneration. Report of the first Greek case and review of the literature.Structural brain indices and executive functioning in multiple sclerosis: A review.Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.Human endogenous retroviruses in multiple sclerosis: potential for novel neuro-pharmacological research.Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications.Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis.Prolonged stimulation of a brainstem raphe region attenuates experimental autoimmune encephalomyelitis.Interleukin-4 induced 1 (IL4I1) promotes central nervous system remyelination.New therapeutic approach by G2013 in experimental model of multiple sclerosis.Impaired Cardiac Function in Patients with Multiple Sclerosis by Comparison with Normal Subjects.A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells.Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imaging.Molecular signature of Epstein-Barr virus infection in MS brain lesions.
P2860
Q26774211-BC2A771A-18FA-494E-8F01-152205DF2655Q26864418-573A5608-CBFE-4424-B44C-56F5E9506CA0Q28078621-0337D897-DEA7-4CDB-BECC-22378E7712F3Q28539087-EF3FAD69-80E1-4921-BC36-D92CC2E4C489Q31095793-0FCB4231-FB5D-4B2C-86D4-B78B66ADDDFFQ31121073-4042A22E-1CD4-4D16-A622-72D2B1A0A29EQ35181321-27B1C5FE-B1A3-4085-B559-D4D71889F2BCQ35532019-F71AE89F-C04B-4589-84CF-D87E63580ED5Q35584727-535B94B7-E498-484B-B944-370F143398E2Q35598836-D41EE57E-5ED7-40D5-8588-A10DAD6B277AQ36038317-8D36C51E-BDAD-45D7-BE3E-53ED150C4531Q36613404-352D7C4F-DDCB-40A1-9C90-BAA3F3526400Q36731484-05BE809D-BA34-4877-8886-D97C52026CC2Q37191533-BF545834-DB64-4171-8346-B2D57AECD87CQ37633504-711C3519-4EF3-4C01-9454-EECF74898D88Q37739872-EB36E8E8-FE4F-4F3C-8B50-00ED816E1CE9Q38050335-A50B5CC6-C230-4AE8-A558-0D96686176CDQ38129953-880FF93B-7137-4ECB-B825-9BE3DA27C3BCQ38174590-7372E1E6-E718-4F13-8336-55DEB4410F2AQ38541861-159B7158-1C1E-448A-AA10-14384AAC8297Q38693549-095F3DCA-4340-4A6A-9271-8B0796FEE11BQ39279957-AAED50A5-BA66-4A5A-9E95-3489C02731F3Q40039485-07236794-C250-4845-896E-A4BCD7120415Q42790335-F48C4068-E39D-4CA8-B9FE-F5642BE0CE7AQ45071794-22704E60-DDA2-43ED-A185-7C37655ECED4Q47719110-578FE3BC-71E9-456C-9B6F-E55057D78458Q48329616-CBE17879-27F3-4D53-BF7E-4CAB868587C0Q48408126-455FD0B0-EDA0-4E6D-A8B9-59CC07916933Q48459061-3C4299C8-9567-49DE-A74F-B0F5B25DC9C6Q49829881-E3918F3A-7FE5-423F-85FE-97779CE6BA18Q52372446-28841502-87EA-4D53-9AE6-BB51ABDFEA40Q55002027-48A6703A-F075-4D2A-B31E-D748E98F865DQ55128564-2F8DA4A8-AEA3-440C-8C53-6FC14F104603
P2860
Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Chronic progressive multiple s ...... on and therapeutic strategies.
@en
type
label
Chronic progressive multiple s ...... on and therapeutic strategies.
@en
prefLabel
Chronic progressive multiple s ...... on and therapeutic strategies.
@en
P2860
P1476
Chronic progressive multiple s ...... on and therapeutic strategies.
@en
P2093
Dirk Fitzner
P2860
P304
P356
10.2174/157015910792246218
P577
2010-09-01T00:00:00Z